References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailChallenges for the development of bone forming agents in Europe: introduction
Kanis, JA; Rizzoli, R; Cooper, C et al

in Osteoporosis International (2014), 25(2), 66-67

Detailed reference viewed: 17 (3 ULg)
Full Text
Peer Reviewed
See detailFurther reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension
Ferrari, S; Adachi, JD; Lippuner, K et al

in Osteoporosis International (2014), 25(2), 56

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailQuality of life benefits of knee arthroplasty for osteoarthritis
NEUPREZ, Audrey ULg; François, Garance ULg; KURTH, William ULg et al

in Osteoporosis International (2014), 25(2), 40

Detailed reference viewed: 28 (6 ULg)
Full Text
Peer Reviewed
See detailEconomic evaluation of an osteoporosis screening campaign: using FRAX as a prescreening tool
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2014), 25(2), 38-39

Detailed reference viewed: 16 (4 ULg)
Full Text
Peer Reviewed
See detailRisk factors for falls among elderly nursing home residents: a 2-year prospective study
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Osteoporosis International (2014), 25(2), 36-37

Detailed reference viewed: 26 (2 ULg)
Full Text
Peer Reviewed
See detailValidity and Reliability of the French version of the STarT Back Screening Tool for patients with low back pain.
Bruyère, Olivier ULg; Demoulin, Maryline; Beaudart, Charlotte ULg et al

in Spine (2014), 39(2), 123-128

Study Design. Observational prospective study.Objective. Our objective was to assess the reliability and validity of the French version of the Keele STarT Back Screening Tool (SBST).Summary of Background ... [more ▼]

Study Design. Observational prospective study.Objective. Our objective was to assess the reliability and validity of the French version of the Keele STarT Back Screening Tool (SBST).Summary of Background Data. The SBST is a recently validated tool developed to identify subgroups of patients with low back pain (LBP) to guide early secondary prevention in primary care.Methods. Outpatients with LBP aged 18 years or more, attending a rehabilitation centre, a back school, a private physiotherapy unit or a fitness centre were included. Patients were assessed through the SBST, Roland-Morris Disability Questionnaire (RMDQ), Orebro Musculoskeletal Pain Screening Questionnaire (OMPSQ), Medical Outcomes Survey Short Form 36 (SF-36) questionnaire, and a pain visual analogic scale (VAS). Test-retest reliability was assessed with Kappa score or the intraclass correlation coefficient (ICC), internal consistency of the psychological subscale with the Cronbach alpha coefficient, construct validity with the Spearman's correlation coefficient, and floor and ceiling effects by percentage frequency of lowest or highest possible score achieved by respondents.Results. 108 patients with LBP were included. The test-retest reliability of the SBST total score was excellent with an ICC of 0.90 (0.81-0.95). The Cronbach alpha coefficient was 0.73 showing a good internal consistency for the psychological subscale. High Spearman's correlation coefficients of 0.74 between SBST and RMDQ, and 0.74 between the SBST and OMPSQ were observed. As expected, low to moderate correlations were observed between the SBST total score and some dissimilar measures of the SF-36. The lowest possible SBST score was observed for 8 patients (7.4%) whereas only three patients (2.8%) had the highest possible SBST score.Conclusion. The French version of the SBST is a reliable and valid questionnaire consistent with the original English version. Therefore, this new version may help French-speaking clinicians and scientists to stratify patients with LBP. [less ▲]

Detailed reference viewed: 42 (13 ULg)
Full Text
Peer Reviewed
See detailEvolution over two years of functional and motor abilities among nursing home residents
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Journal of Frailty & Aging (2014), 3(1), 45

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailPrevalence of sarcopenia according to different diagnostic tools
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Slomian, Justine ULg et al

in Journal of Frailty & Aging (2014), 3(1), 43

Detailed reference viewed: 47 (11 ULg)
Full Text
Peer Reviewed
See detailVitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux, Christian; Binkley, Neil; Boonen, Steven et al

in Calcified tissue international (2014), 94(2), 153-7

Vitamin D supplementation is recommended for women with osteoporosis. In the FOCUS-D trial comparing the combination tablet alendronate plus vitamin D3 5,600 IU (ALN/D) with standard care (SC) prescribed ... [more ▼]

Vitamin D supplementation is recommended for women with osteoporosis. In the FOCUS-D trial comparing the combination tablet alendronate plus vitamin D3 5,600 IU (ALN/D) with standard care (SC) prescribed by patients' personal physicians, ALN/D was more effective in improving serum 25(OH)D and bone turnover markers by 6 months and increasing spine and hip bone mineral density (BMD) after 1 year than SC. This post hoc analysis examined the relationship between BMD gain and 25(OH)D in women in SC receiving alendronate (SC/ALN, n = 134, 52% of the SC group) and in the ALN/D group (n = 257). At baseline, participants were of mean age 73 years and 72% were Caucasian, with a mean 25(OH)D of 14.9 ng/mL. In the SC/ALN group, most received vitamin D, although intake of vitamin D varied extensively (51% received <400 mug/day). In this group, end-of-study 25(OH)D correlated positively with mean percent increases from baseline in lumbar spine and femoral neck BMD [Pearson correlation coefficients (95% CI) = 0.23 (0.02-0.41) and 0.24 (0.03-0.41), respectively]. Baseline 25(OH)D correlated with increases in only lumbar spine BMD [Pearson correlation coefficient (95% CI) = 0.22 (0.01-0.40)]. No correlations between mean BMD change and 25(OH)D were seen with ALN/D. In conclusion, in postmenopausal women with osteoporosis and low 25(OH)D receiving alendronate and a wide range of vitamin D doses, the increase in lumbar spine and femoral neck BMD was positively correlated with serum 25(OH)D achieved by the end of the study and, to some extent, with 25(OH)D concentrations at baseline. The degree of success of alendronate therapy for osteoporosis may depend on the vitamin D status of patients. [less ▲]

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailRepublished: Value of biomarkers in osteoarthritis: current status and perspectives.
Lotz, M.; Martel-Pelletier, J.; Christiansen, C. et al

in Postgraduate Medical Journal (2014), 90(1061), 171-8

Osteoarthritis affects the whole joint structure with progressive changes in cartilage, menisci, ligaments and subchondral bone, and synovial inflammation. Biomarkers are being developed to quantify joint ... [more ▼]

Osteoarthritis affects the whole joint structure with progressive changes in cartilage, menisci, ligaments and subchondral bone, and synovial inflammation. Biomarkers are being developed to quantify joint remodelling and disease progression. This article was prepared following a working meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis convened to discuss the value of biochemical markers of matrix metabolism in drug development in osteoarthritis. The best candidates are generally molecules or molecular fragments present in cartilage, bone or synovium and may be specific to one type of joint tissue or common to them all. Many currently investigated biomarkers are associated with collagen metabolism in cartilage or bone, or aggrecan metabolism in cartilage. Other biomarkers are related to non-collagenous proteins, inflammation and/or fibrosis. Biomarkers in osteoarthritis can be categorised using the burden of disease, investigative, prognostic, efficacy of intervention, diagnostic and safety classification. There are a number of promising candidates, notably urinary C-terminal telopeptide of collagen type II and serum cartilage oligomeric protein, although none is sufficiently discriminating to differentiate between individual patients and controls (diagnostic) or between patients with different disease severities (burden of disease), predict prognosis in individuals with or without osteoarthritis (prognostic) or perform so consistently that it could function as a surrogate outcome in clinical trials (efficacy of intervention). Future avenues for research include exploration of underlying mechanisms of disease and development of new biomarkers; technological development; the 'omics' (genomics, metabolomics, proteomics and lipidomics); design of aggregate scores combining a panel of biomarkers and/or imaging markers into single diagnostic algorithms; and investigation into the relationship between biomarkers and prognosis. [less ▲]

Detailed reference viewed: 18 (7 ULg)
Full Text
Peer Reviewed
See detailCorrection of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients.
Rizzoli, R.; Dawson-Hughes, B.; Kaufman, J.-M. et al

in European Journal of Endocrinology (2014), 170(3), 441-50

OBJECTIVE: This study aims to investigate the efficacy and safety of oral fixed-dose combination of strontium ranelate 2 g/vitamin D3 1000 IU daily vs strontium ranelate 2 g daily for correcting vitamin D ... [more ▼]

OBJECTIVE: This study aims to investigate the efficacy and safety of oral fixed-dose combination of strontium ranelate 2 g/vitamin D3 1000 IU daily vs strontium ranelate 2 g daily for correcting vitamin D insufficiency in osteoporosis. DESIGN: A 6-month international, randomized, double-blind, parallel-group, phase 3 study. METHODS: A total of 518 men and postmenopausal women aged >/=50 years with primary osteoporosis (T-score </=-2.5 s.d.) and serum 25-hydroxyvitamin D (25(OH)D) >22.5 nmol/l were included. Patients were allocated to strontium ranelate 2 g/vitamin D3 1000 IU daily (n=413) or strontium ranelate 2 g daily (n=105). The participants received calcium 1 g daily. The primary endpoint was serum 25(OH)D at last post-baseline evaluation during 3 months. RESULTS: Both groups were comparable at baseline. Mean baseline of 25(OH)D was 44.1+/-14.6 nmol/l. After 3 months, the percentage of patients with 25(OH)D >/=50 nmol/l was higher with strontium ranelate/vitamin D3 vs strontium ranelate (84 vs 44%, P<0.001; adjusted between-group odds ratio=6.7; 95% CI, 4.2-10.9). The efficacy of the fixed-dose combination on 25(OH)D was maintained at 6 months (86 vs 40%, P<0.001). Mean 25(OH)D was 65.1 and 49.5 nmol/l, respectively, after 3 months and 66.9 and 45.4 nmol/l after 6 months. Physical performance improved in both groups. Falls were 17 and 20% in the strontium ranelate/vitamin D3 and strontium ranelate groups respectively. Parathyroid hormone levels were inversely correlated with 25(OH)D. No clinically relevant differences in safety were observed. CONCLUSIONS: This study confirms the efficacy and safety of fixed-dose combination of strontium ranelate 2 g/vitamin D3 1000 IU for correction of vitamin D insufficiency in osteoporotic patients. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailCardiovascular safety of strontium ranelate: real-life assessment in clinical practice.
Donneau, Anne-Françoise ULg; Reginster, Jean-Yves ULg

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014), 25

Detailed reference viewed: 24 (15 ULg)
Full Text
Peer Reviewed
See detailResponse to Dr Bolland's eLetter: Strontium and cardiovascular events.
REGINSTER, Jean-Yves ULg

in Annals of the rheumatic diseases (2014), 73(2), 9

Detailed reference viewed: 7 (2 ULg)